WEBULL

How Investors May Respond To iRhythm Technologies (IRTC) Securities Lawsuit Advancing After FDA Non-Conformity Findings

Simply Wall St · 09/24/2025 14:45
  • In the past week, Kahn Swick & Foti, LLC announced it is continuing its investigation into iRhythm Technologies following a court decision to let a securities class action lawsuit proceed against the company and certain executives, tied to prior FDA findings of non-conformities in the Zio AT System and alleged disclosure issues.
  • This development raises significant concerns about corporate governance and the potential impact of regulatory and legal risks on iRhythm’s business operations.
  • We will consider how progressing securities litigation over regulatory non-compliance may reshape iRhythm Technologies' investment narrative going forward.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

iRhythm Technologies Investment Narrative Recap

To remain confident in iRhythm Technologies, an investor needs to believe the company can maintain leadership in digital cardiac monitoring despite ongoing competition and regulatory scrutiny. The recent class action lawsuit and continued regulatory spotlight may raise the near-term risk profile, but the most critical catalyst, growing adoption of Zio solutions in mainstream and international healthcare settings, appears unaffected for now. The legal proceedings, while material, do not yet alter the expected trajectory for core revenue drivers or immediate product uptake.

Among the latest developments, the AMALFI trial’s positive results highlight the Zio LTCM service’s capability in detecting atrial fibrillation in high-risk patients, aligning with the main growth catalyst: expanding utilization beyond traditional cardiology and entering broader markets. This clinical validation supports the investment thesis, even as regulatory compliance and disclosure issues remain an ongoing concern in the background.

But with these legal and regulatory overhangs still unresolved, investors should be mindful of…

Read the full narrative on iRhythm Technologies (it's free!)

iRhythm Technologies' outlook anticipates $1.1 billion in revenue and $49.7 million in earnings by 2028. This reflects a 17.5% annual revenue growth rate and an increase in earnings of $142.1 million from a current loss of $-92.4 million.

Uncover how iRhythm Technologies' forecasts yield a $182.62 fair value, a 4% upside to its current price.

Exploring Other Perspectives

IRTC Community Fair Values as at Sep 2025
IRTC Community Fair Values as at Sep 2025

Four Simply Wall St Community members assigned iRhythm’s fair value from US$74.68 to US$182.62 per share, reflecting a broad range of outlooks. While you consider these differing opinions, remember that persistent regulatory and litigation risks could continue to influence the company’s progress.

Explore 4 other fair value estimates on iRhythm Technologies - why the stock might be worth less than half the current price!

Build Your Own iRhythm Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.